A citation-based method for searching scientific literature

Gaia Griguolo, Maria Vittoria Dieci, Valentina Guarneri, PierFranco Conte. Expert Rev Anticancer Ther 2018
Times Cited: 29







List of co-cited articles
162 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
27

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
20

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.
Junko Murai, Shar-yin N Huang, Benu Brata Das, Amelie Renaud, Yiping Zhang, James H Doroshow, Jiuping Ji, Shunichi Takeda, Yves Pommier. Cancer Res 2012
20

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
20

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
17

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin,[...]. N Engl J Med 2018
899
17

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
17


Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
13

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
13

Mechanisms of PARP inhibitor sensitivity and resistance.
Alan D D'Andrea. DNA Repair (Amst) 2018
209
13

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
13

Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.
Jung-Min Lee, John L Hays, Christina M Annunziata, Anne M Noonan, Lori Minasian, Jo Anne Zujewski, Minshu Yu, Nicolas Gordon, Jiuping Ji, Tristan M Sissung,[...]. J Natl Cancer Inst 2014
140
10

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
679
10

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
Ruth Plummer, Helen Swaisland, Karin Leunen, Carla M L van Herpen, Guy Jerusalem, Jacques De Grève, Martijn P Lolkema, Patricia Soetekouw, Morten Mau-Sørensen, Dorte Nielsen,[...]. Cancer Chemother Pharmacol 2015
36
10

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Karen A Gelmon, Marc Tischkowitz, Helen Mackay, Kenneth Swenerton, André Robidoux, Katia Tonkin, Hal Hirte, David Huntsman, Mark Clemons, Blake Gilks,[...]. Lancet Oncol 2011
831
10

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
Bella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, M William Audeh, Michael Friedlander, Judith Balmaña, Gillian Mitchell, Georgeta Fried, Salomon M Stemmer, Ayala Hubert,[...]. J Clin Oncol 2015
10

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
10

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib.
J Mateo, V Moreno, A Gupta, S B Kaye, E Dean, M R Middleton, M Friedlander, C Gourley, R Plummer, G Rustin,[...]. Target Oncol 2016
86
10

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Wataru Sakai, Elizabeth M Swisher, Beth Y Karlan, Mukesh K Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas, Céline Jacquemont, Daniel J Farrugia, Fergus J Couch,[...]. Nature 2008
720
10

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.
J Balmaña, N M Tung, S J Isakoff, B Graña, P D Ryan, C Saura, E S Lowe, P Frewer, E Winer, J Baselga,[...]. Ann Oncol 2014
110
10

Current status of poly(ADP-ribose) polymerase inhibitors and future directions.
Akihiro Ohmoto, Shinichi Yachida. Onco Targets Ther 2017
81
10

PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
Benjamin G Bitler, Zachary L Watson, Lindsay J Wheeler, Kian Behbakht. Gynecol Oncol 2017
131
10

Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.
Matthew D Burstein, Anna Tsimelzon, Graham M Poage, Kyle R Covington, Alejandro Contreras, Suzanne A W Fuqua, Michelle I Savage, C Kent Osborne, Susan G Hilsenbeck, Jenny C Chang,[...]. Clin Cancer Res 2015
691
10

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Brian D Lehmann, Joshua A Bauer, Xi Chen, Melinda E Sanders, A Bapsi Chakravarthy, Yu Shyr, Jennifer A Pietenpol. J Clin Invest 2011
10

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
10

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
10

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Sung-Bae Kim, Rebecca Dent, Seock-Ah Im, Marc Espié, Sibel Blau, Antoinette R Tan, Steven J Isakoff, Mafalda Oliveira, Cristina Saura, Matthew J Wongchenko,[...]. Lancet Oncol 2017
274
10

PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
Yasir H Ibrahim, Celina García-García, Violeta Serra, Lei He, Kristine Torres-Lockhart, Aleix Prat, Pilar Anton, Patricia Cozar, Marta Guzmán, Judit Grueso,[...]. Cancer Discov 2012
390
10

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
Brian D Lehmann, Bojana Jovanović, Xi Chen, Monica V Estrada, Kimberly N Johnson, Yu Shyr, Harold L Moses, Melinda E Sanders, Jennifer A Pietenpol. PLoS One 2016
611
10

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
10


A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Richard H Wilson, Tr Jeffry Evans, Mark R Middleton, L Rhoda Molife, James Spicer, Veronique Dieras, Patricia Roxburgh, Heidi Giordano, Sarah Jaw-Tsai, Sandra Goble,[...]. Br J Cancer 2017
52
10

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941.
Teemu T Junttila, Robert W Akita, Kathryn Parsons, Carter Fields, Gail D Lewis Phillips, Lori S Friedman, Deepak Sampath, Mark X Sliwkowski. Cancer Cell 2009
587
10

Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.
Fabrice André, Eva Ciruelos, Gabor Rubovszky, Mario Campone, Sibylle Loibl, Hope S Rugo, Hiroji Iwata, Pierfranco Conte, Ingrid A Mayer, Bella Kaufman,[...]. N Engl J Med 2019
966
10

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
10

Talazoparib: First Global Approval.
Sheridan M Hoy. Drugs 2018
68
10

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
725
10

Olaparib.
Sylvia Bochum, Stephanie Berger, Uwe M Martens. Recent Results Cancer Res 2018
34
10

Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.
Kathleen E Malone, Janet R Daling, David R Doody, Li Hsu, Leslie Bernstein, Ralph J Coates, Polly A Marchbanks, Michael S Simon, Jill A McDonald, Sandra A Norman,[...]. Cancer Res 2006
227
6

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer.
Jung-Min Lee, John L Hays, Victoria L Chiou, Christina M Annunziata, Elizabeth M Swisher, Maria I Harrell, Minshu Yu, Nicolas Gordon, Tristan M Sissung, Jiuping Ji,[...]. Oncotarget 2017
26
7

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.
Andrew Tutt, Holly Tovey, Maggie Chon U Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazinska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett-Lee,[...]. Nat Med 2018
450
6

Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours.
G Del Conte, C Sessa, R von Moos, L Viganò, T Digena, A Locatelli, E Gallerani, A Fasolo, A Tessari, R Cathomas,[...]. Br J Cancer 2014
79
6

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.
Ruud van der Noll, Serena Marchetti, Neeltje Steeghs, Jos H Beijnen, Marja W J Mergui-Roelvink, Emmy Harms, Harriet Rehorst, Gabe S Sonke, Jan H M Schellens. Br J Cancer 2015
34
6

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Joyce F Liu, Sara M Tolaney, Michael Birrer, Gini F Fleming, Mary K Buss, Suzanne E Dahlberg, Hang Lee, Christin Whalen, Karin Tyburski, Eric Winer,[...]. Eur J Cancer 2013
120
6

Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer.
Jung-Min Lee, Cody J Peer, Minshu Yu, Lauren Amable, Nicolas Gordon, Christina M Annunziata, Nicole Houston, Andrew K L Goey, Tristan M Sissung, Bernard Parker,[...]. Clin Cancer Res 2017
34
6

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer.
U A Matulonis, G M Wulf, W T Barry, M Birrer, S N Westin, S Farooq, K M Bell-McGuinn, E Obermayer, C Whalen, T Spagnoletti,[...]. Ann Oncol 2017
133
6

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Fergus J Couch, Steven N Hart, Priyanka Sharma, Amanda Ewart Toland, Xianshu Wang, Penelope Miron, Janet E Olson, Andrew K Godwin, V Shane Pankratz, Curtis Olswold,[...]. J Clin Oncol 2015
407
6

4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1.
Keith A Menear, Claire Adcock, Robert Boulter, Xiao-ling Cockcroft, Louise Copsey, Aaron Cranston, Krystyna J Dillon, Jan Drzewiecki, Sheila Garman, Sylvie Gomez,[...]. J Med Chem 2008
378
6

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Jonathan A Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra,[...]. Lancet Oncol 2016
284
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.